|
|
|
Insider
Information: |
Shabet Rose Sharon |
Relationship: |
|
City: |
Greenwich |
State: |
CT |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
18 |
|
Direct
Shares |
0 |
|
Indirect Shares
|
415,583,308 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$3,559,169,249 |
|
|
Total
Shares |
415,583,308 |
|
|
Total
Value |
$3,559,169,249 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
8
|
Stock
price went up :
|
1
|
2
|
Stock
price went down : |
0
|
6
|
|
|
|
Gain/Loss Ratio : |
1.0
|
1.0
|
Percentage
Gain/Loss : |
183.9%
|
-164.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Tekmira Pharmaceuticals Corp |
TKMR |
10% Owner |
|
0 |
2017-07-01 |
16,013,540 |
Premium* |
|
Sio Gene Therapies Inc |
SIOX |
10% Owner |
|
0 |
2019-03-18 |
105,952,381 |
Premium* |
|
Myovant Sciences Ltd. |
MYOV |
10% Owner |
|
0 |
2019-06-04 |
40,765,599 |
Premium* |
|
Urovant Sciences Ltd. |
UROV |
10% Owner |
2018-10-01 |
0 |
2019-06-19 |
22,860,013 |
Premium* |
|
Adaptive Biotechnologies Corp |
ADPT |
10% Owner |
|
0 |
2020-12-14 |
29,993,708 |
Premium* |
|
Bridgebio Pharma, Inc. |
BBIO |
|
2019-06-27 |
0 |
2023-07-18 |
25,120,991 |
Premium* |
|
Zentalis Pharmaceuticals, Llc |
ZNTL |
10% Owner |
|
0 |
2020-12-01 |
3,943,284 |
Premium* |
|
Inhibrx, Inc. |
INBX |
|
2020-08-24 |
0 |
2023-08-28 |
7,150,826 |
Premium* |
|
4d Molecular Therapeutics Inc. |
FDMT |
|
2020-12-15 |
0 |
2024-01-04 |
4,247,914 |
Premium* |
|
Rallybio Corp |
RLYB |
10% Owner |
2021-07-29 |
0 |
2021-07-29 |
4,194,777 |
Premium* |
|
Figs, Inc. |
FIGS |
10% Owner |
2021-09-02 |
0 |
2021-09-03 |
14,742,689 |
Premium* |
|
Procept Biorobotics Corp |
PRCT |
|
|
0 |
2021-09-14 |
308,142 |
Premium* |
|
Ginkgo Bioworks Holdings, Inc |
DNA |
|
|
0 |
2022-03-02 |
51,055,144 |
Premium* |
|
Amylyx Pharmaceuticals, Inc. |
AMLX |
|
2022-01-11 |
0 |
2022-01-11 |
2,300,000 |
Premium* |
|
Frazier Lifesciences Acquisition... |
FLAC |
|
2022-11-02 |
0 |
2022-11-02 |
1,211,582 |
Premium* |
|
Rayzebio, Inc. |
RYZB |
|
2023-09-19 |
0 |
2024-02-26 |
0 |
Premium* |
|
Api Group Corp |
APG |
|
2024-01-02 |
0 |
2024-03-05 |
27,071,548 |
Premium* |
|
Fluidigm Corp |
FLDM |
|
|
0 |
2024-03-18 |
58,651,170 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
FLDM |
Fluidigm Corp |
|
|
2024-03-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
58,651,170 |
|
% |
|
APG |
Api Group Corp |
|
|
2024-03-05 |
4 |
S |
$34.25 |
$104,072,632 |
I/I |
(3,038,617) |
39,032 |
0 |
% |
|
APG |
Api Group Corp |
|
|
2024-02-28 |
4 |
D |
$36.90 |
$149,999,939 |
I/I |
(4,065,039) |
99,804 |
0 |
- |
|
APG |
Api Group Corp |
|
|
2024-02-28 |
4 |
OE |
$24.60 |
$201,741,599 |
I/I |
8,200,878 |
181,104 |
0 |
- |
|
RYZB |
Rayzebio, Inc. |
|
|
2024-02-26 |
4 |
D |
$0.00 |
$0 |
I/I |
(6,642,700) |
0 |
0 |
- |
|
FDMT |
4d Molecular Therapeutics... |
|
|
2024-01-04 |
4 |
S |
$19.53 |
$10,546,200 |
I/I |
(540,000) |
4,247,914 |
0 |
- |
|
APG |
Api Group Corp |
|
|
2024-01-02 |
4 |
S |
$31.30 |
$203,450,000 |
I/I |
(6,500,000) |
17,088 |
0 |
% |
|
RYZB |
Rayzebio, Inc. |
|
|
2023-09-19 |
4 |
B |
$18.00 |
$25,000,002 |
I/I |
1,388,889 |
1,743,556 |
0.01 |
% |
|
RYZB |
Rayzebio, Inc. |
|
|
2023-09-19 |
4 |
A |
$0.00 |
$0 |
I/I |
5,253,811 |
1,285,223 |
0 |
- |
|
INBX |
Inhibrx, Inc. |
|
|
2023-08-28 |
4 |
B |
$19.35 |
$9,899,982 |
I/I |
511,627 |
511,627 |
0.01 |
- |
|
BBIO |
Bridgebio Pharma, Inc. |
|
|
2023-07-18 |
4 |
S |
$35.00 |
$52,500,000 |
I/I |
(1,500,000) |
25,120,991 |
0 |
% |
|
FDMT |
4d Molecular Therapeutics... |
|
|
2023-05-09 |
4 |
B |
$16.00 |
$13,600,000 |
I/I |
850,000 |
4,787,914 |
0.01 |
- |
|
FLAC |
Frazier Lifesciences Acqu... |
|
|
2022-11-02 |
4 |
B |
$10.08 |
$8,538,385 |
I/I |
847,062 |
1,211,582 |
0.01 |
- |
|
INBX |
Inhibrx, Inc. |
|
|
2022-10-07 |
4 |
B |
$30.00 |
$39,999,857 |
I/I |
1,333,333 |
333,333 |
0.01 |
- |
|
DNA |
Ginkgo Bioworks Holdings,... |
|
|
2022-03-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(288,000,000) |
51,055,144 |
0 |
- |
|
AMLX |
Amylyx Pharmaceuticals, I... |
|
|
2022-01-11 |
4 |
B |
$19.00 |
$43,700,000 |
I/I |
2,300,000 |
2,300,000 |
0.01 |
- |
|
AMLX |
Amylyx Pharmaceuticals, I... |
|
|
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
4,870,536 |
4,870,536 |
0 |
- |
|
DNA |
Ginkgo Bioworks Holdings,... |
10% Owner |
|
2021-09-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
339,055,144 |
|
% |
|
PRCT |
Procept Biorobotics Corp |
|
|
2021-09-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
308,142 |
|
- |
|
FIGS |
Figs, Inc. |
10% Owner |
|
2021-09-03 |
4 |
S |
$44.92 |
$1,905,192 |
I/I |
(42,413) |
14,742,689 |
0 |
% |
|
FIGS |
Figs, Inc. |
10% Owner |
|
2021-09-02 |
4 |
S |
$47.28 |
$7,450,713 |
I/I |
(157,587) |
14,785,102 |
0 |
% |
|
RLYB |
Rallybio Corp |
10% Owner |
|
2021-07-29 |
4 |
B |
$13.00 |
$10,478,000 |
I/I |
806,000 |
4,194,777 |
1.5 |
- |
|
RLYB |
Rallybio Corp |
10% Owner |
|
2021-07-29 |
4 |
A |
$0.00 |
$0 |
I/I |
3,388,777 |
3,388,777 |
0 |
- |
|
FDMT |
4d Molecular Therapeutics... |
10% Owner |
|
2020-12-15 |
4 |
B |
$23.00 |
$25,300,000 |
I/I |
1,100,000 |
3,937,914 |
1.5 |
- |
|
FDMT |
4d Molecular Therapeutics... |
10% Owner |
|
2020-12-15 |
4 |
A |
$0.00 |
$0 |
I/I |
2,837,914 |
2,837,914 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|